Palynziq Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved diagnosis of phenylketonuria, clinical success of enzyme substitution therapies, expansion of rare disease treatment programs, increased awareness among adult PKU patients, availability of specialty metabolic clinics.

The growth in the forecast period can be attributed to growing investments in rare disease drug development, expansion of newborn screening programs, increasing adoption of lifelong PKU management strategies, rising reimbursement support for orphan drugs, advancement of enzyme engineering technologies. Major trends in the forecast period include increasing adoption of enzyme replacement therapies, rising focus on rare metabolic disorder treatments, expansion of personalized pku management, growing emphasis on long-term metabolic control, enhanced patient monitoring and support programs.

The growing awareness of genetic disorders is expected to drive the growth of the Palynziq market going forward. Genetic disorders are medical conditions caused by DNA abnormalities, ranging from single-gene mutations to complex chromosomal alterations. Awareness of these disorders is increasing due to factors such as broader access to genetic testing through advanced genomic sequencing, affordable at-home DNA testing kits, global health campaigns promoting early diagnosis, and the integration of genetic education into healthcare systems. As patients and healthcare providers become more informed about treatment options, demand for therapies like Palynziq rises. For instance, in July 2025, according to the Adult Polyglucosan Body Disease (APBD) Research Foundation, a US-based nonprofit organization, a study on GBE1-related rare genetic diseases updated the global prevalence estimate from 1 in 325,000 in 2022 to 1 in 236,000 in 2025, suggesting about 34,000 people worldwide could be affected, reflecting improved detection and reporting. Therefore, growing awareness of genetic disorders is driving the Palynziq market.

Major companies in the Palynziq market are focusing on innovative solutions such as expanded post-marketing surveillance (PMS) and late-stage clinical studies to meet the rising demand for long-term drug safety monitoring, regulatory compliance, and evidence-based confidence in treatment outcomes for phenylketonuria (PKU). Post-marketing surveillance evaluates real-world safety and effectiveness beyond initial approval, providing broader clinical insights than pre-approval trials. For instance, in April 2025, BioMarin Pharmaceutical, a US-based company, reported that the Phase 3 PEGASUS trial evaluating Palynziq (pegvaliase-pqpz) met its primary efficacy endpoint, showing a statistically significant reduction in blood phenylalanine (Phe) levels in adolescents aged 12-17 with PKU compared to diet alone. This reinforced Palynziq’s long-term therapeutic value and supported ongoing PMS research for safety and efficacy.

In November 2023, Elliott Investment Management L.P., a US-based investment firm, acquired a $1 billion stake in BioMarin Pharmaceutical. This acquisition reflects a strategic reassessment and transition period for BioMarin, influenced by internal leadership changes and external investor engagement. BioMarin Pharmaceutical specializes in rare and genetic disease therapies, including Palynziq.

Major companies operating in the palynziq market are BioMarin Pharmaceutical Inc.

North America was the largest region in the palynziq market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the palynziq market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the palynziq market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the palynziq market by increasing costs related to imported biologic enzymes, advanced fermentation equipment, cold-chain logistics, and specialized packaging materials. North America and Europe are particularly affected due to dependence on complex biologics manufacturing and cross-border supply networks, while emerging markets face elevated import expenses. These tariffs are contributing to higher therapy costs and slower market penetration. At the same time, they are encouraging regional biologics manufacturing, domestic enzyme production, and strengthened local supply ecosystems for rare disease treatments.

The palynziq market research report is one of a series of new reports that provides palynziq market statistics, including palynziq industry global market size, regional shares, competitors with a palynziq market share, detailed palynziq market segments, market trends and opportunities, and any further data you may need to thrive in the palynziq industry. This palynziq market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Palynziq is the brand name for pegvaliase-pqpz, a biologic medication used to treat phenylketonuria (PKU), a rare genetic disorder in which the body cannot metabolize phenylalanine, an amino acid present in food. The drug provides an enzyme that breaks down phenylalanine in the blood, lowering its levels and preventing neurological damage caused by elevated phenylalanine concentrations.

The main indications for Palynziq include phenylketonuria (PKU) and other related metabolic disorders. Phenylketonuria is a genetic condition marked by a deficiency of the enzyme phenylalanine hydroxylase, resulting in an inability to properly metabolize phenylalanine. It is distributed through pharmacies and online pharmacies and is used by end users including hospitals, specialty clinics, and home care settings.

The palynziq market consists of sales of pre-filled syringes, treatment kits, multi-dose vials, patient kits (with accessories), and unit dose packs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.